CPHI Quote, Financials, Valuation and Earnings

Linike Medical Group has a net margin of -101.61% compared to China Pharma Holding's net margin of --. China Pharma Holding's return on equity of -66.27% beat Linike Medical Group's return on equity of --.

China Pharma Holding has a consensus price target of --, signalling downside risk potential of --. On the other hand Linike Medical Group has an analysts' consensus of -- which suggests that it could grow by 27556.82%. Given that Linike Medical Group has higher upside potential than China Pharma Holding, analysts believe Linike Medical Group is more attractive than China Pharma Holding.

China Pharma Holding has a beta of 0.661, which suggesting that the stock is 33.874% less volatile than S&P 500. In comparison Linike Medical Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

China Pharma Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Linike Medical Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Pharma Holding pays -- of its earnings as a dividend. Linike Medical Group pays out -- of its earnings as a dividend.

China Pharma Holding quarterly revenues are $1.1M, which are larger than Linike Medical Group quarterly revenues of --. China Pharma Holding's net income of -$1.1M is higher than Linike Medical Group's net income of --. Notably, China Pharma Holding's price-to-earnings ratio is -- while Linike Medical Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Pharma Holding is 0.46x versus -- for Linike Medical Group. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -101.61% compared to China Pharma Holding's net margin of -49.65%. China Pharma Holding's return on equity of -66.27% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

China Pharma Holding has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 620.92%. Given that NovaBay Pharmaceuticals has higher upside potential than China Pharma Holding, analysts believe NovaBay Pharmaceuticals is more attractive than China Pharma Holding.

China Pharma Holding has a beta of 0.661, which suggesting that the stock is 33.874% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

China Pharma Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Pharma Holding pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

China Pharma Holding quarterly revenues are $1.1M, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. China Pharma Holding's net income of -$1.1M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, China Pharma Holding's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Pharma Holding is 0.46x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -101.61% compared to China Pharma Holding's net margin of -2357.27%. China Pharma Holding's return on equity of -66.27% beat Palatin Technologies's return on equity of --.

China Pharma Holding has a consensus price target of --, signalling downside risk potential of --. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1652.58%. Given that Palatin Technologies has higher upside potential than China Pharma Holding, analysts believe Palatin Technologies is more attractive than China Pharma Holding.

China Pharma Holding has a beta of 0.661, which suggesting that the stock is 33.874% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

China Pharma Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Pharma Holding pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

China Pharma Holding quarterly revenues are $1.1M, which are larger than Palatin Technologies quarterly revenues of $350K. China Pharma Holding's net income of -$1.1M is higher than Palatin Technologies's net income of -$7.8M. Notably, China Pharma Holding's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Pharma Holding is 0.46x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Yubo International Biotech has a net margin of -101.61% compared to China Pharma Holding's net margin of -11740.4%. China Pharma Holding's return on equity of -66.27% beat Yubo International Biotech's return on equity of --.

China Pharma Holding has a consensus price target of --, signalling downside risk potential of --. On the other hand Yubo International Biotech has an analysts' consensus of -- which suggests that it could fall by --. Given that China Pharma Holding has higher upside potential than Yubo International Biotech, analysts believe China Pharma Holding is more attractive than Yubo International Biotech.

China Pharma Holding has a beta of 0.661, which suggesting that the stock is 33.874% less volatile than S&P 500. In comparison Yubo International Biotech has a beta of 2.982, suggesting its more volatile than the S&P 500 by 198.196%.

China Pharma Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Yubo International Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Pharma Holding pays -- of its earnings as a dividend. Yubo International Biotech pays out -- of its earnings as a dividend.

China Pharma Holding quarterly revenues are $1.1M, which are larger than Yubo International Biotech quarterly revenues of $3.5K. China Pharma Holding's net income of -$1.1M is lower than Yubo International Biotech's net income of -$580.8K. Notably, China Pharma Holding's price-to-earnings ratio is -- while Yubo International Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Pharma Holding is 0.46x versus 12.12x for Yubo International Biotech. Usually stocks with elevated PS ratios are considered overvalued.